Related Experiment Video

Updated: Dec 22, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K

Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer

Parker L Bussies1, Matthew Schlumbrecht1,2

  • 1Miller School of Medicine, University of Miami, Miami, Florida, USA.

The Oncologist
|May 6, 2020
PubMed

Insights

This study explored combining anti-estrogenic therapy with a MEK-inhibitor for recurrent low-grade serous ovarian carcinoma (LGSOC). The combination showed promise, offering 9 months of progression-free survival in a heavily pretreated patient.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Low-grade serous ovarian carcinoma (LGSOC) often presents with chemoresistance.
  • Limited effective treatment options exist for recurrent LGSOC, frequently relying on hormone antagonism.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a combination therapy for heavily pretreated, estrogen receptor-positive, recurrent LGSOC.
  • To investigate the potential synergistic effect of combining endocrine therapy with a MEK-inhibitor in a clinical setting.

Main Methods:

  • A case study involving a heavily pretreated patient with estrogen receptor-positive, recurrent LGSOC.
  • Administration of a dual-therapy regimen comprising an anti-estrogenic agent (fulvestrant) and a MEK-inhibitor (trametinib).

Main Results:

  • The combination therapy was well tolerated by the patient.
  • The dual-therapy regimen appeared to provide 9 months of progression-free survival.

Conclusions:

  • Combination anti-estrogenic and MEK-inhibitor therapy may be a viable treatment strategy for recurrent LGSOC.
  • Further clinical investigation is warranted to validate these preliminary findings and explore the therapeutic potential.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K